Prescription medicine
Mecasermin Brand names: Increlex
Mecasermin (Increlex) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the mecasermin FDA label on DailyMed (effective August 5, 2025); every mecasermin label on DailyMed.
Highlights of the record
FDA label of August 5, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageINCRELEX (mecasermin) injection is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.
Forms and strengths
- 40 mg/4ml
Injection (solution); injection.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 2 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 809 through July 30, 2026
What is mecasermin used for?
From the label: indications and usageINCRELEX (mecasermin) injection is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. ( 1 ) Limitations of use: INCRELEX is not a substitute to GH for approved GH indications. Severe Primary IGF-1 Deficiency (Primary IGFD) INCRELEX is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with: severe primary IGF-1 deficiency or growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. […]
Source: FDA drug label (Increlex), Ipsen Biopharmaceuticals, Inc., effective August 5, 2025 (SPL set a8b27a1b-a611-4f91-ad22-76d4b390c3ae), via openFDA; the full label on DailyMed
Is there a generic for mecasermin (Increlex)?
No generic mecasermin is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for mecasermin?
The FDA Adverse Event Reporting System holds 809 reports that list mecasermin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 24 are coded as a death and 219 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Mecasermin side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other